Neuphoria Closes Phase 3 BNC210 Enrollment, Files $15.48M At-the-Market Raise

Introduction

NEUPHORIA THERAPEUTICS INC (NASDAQ: NEUP) is a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders. Headquartered in Burlington, Massachusetts, with research and development operations in Adelaide, Australia, the firm’s lead candidate, BNC210, is developed as a non-sedating anti-anxiety therapy.

Corporate Structure

Neuphoria operates under the ticker NEUP on the Nasdaq Stock Market. The company traces its origins back more than 20 years in Adelaide, where its founding research team established expertise in ion channel biology and translational medicine. Its cross-continental workforce includes scientists and clinicians such as Liz Doolin, Dharam Paul, Michael Odontiadis, and Julia Crossman. Neuphoria has a Board of Directors and is led by President and CEO Spyros Papapetropoulos, M.D., Ph.D. The total number of employees is not publicly disclosed.

Neuropsychiatric therapy by Natasha Connell

Recent Developments and News

• On September 4, 2025, Neuphoria announced the completion of target enrollment (332 participants) in the Phase 3 AFFIRM-1 trial of BNC210 for Social Anxiety Disorder (SAD). Topline data are anticipated in early Q4 2025.
• On October 20, 2025, the company filed a prospectus supplement (Rule 424(b)(5)) with the SEC to raise up to $15,478,160 through an at-the-market equity offering, with H.C. Wainwright & Co. acting as sales agent. The last reported sale price of the common stock was $15.52 per share as of October 17, 2025.
• In July 2024, Neuphoria regained compliance with Nasdaq’s $1.00 minimum bid-price requirement after its American Depositary Shares briefly fell below that threshold.

Financial and Strategic Analysis

As of October 21, 2025, NEUP closed at $4.9970 per share, reflecting a year-to-date decline of 67.55% on a volume of 777,862 shares traded. To support its clinical programs and general operations, Neuphoria has implemented a capital-raising strategy through its at-the-market offering agreement. Management intends to deploy proceeds toward ongoing trials and pipeline development.

Strategically, the company’s pipeline includes:

• BNC210: A selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, currently under FDA Fast Track designation for SAD and post-traumatic stress disorder (PTSD).
• Next-generation NAM series targeting additional neuropsychiatric conditions.
• Kv3.1/Kv3.2 potassium channel agonists for potential treatment of cognitive disorders, supported by preclinical evidence.

Market Position and Industry Context

Neuphoria operates in a competitive landscape that includes selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines, which are sometimes associated with sedation, cognitive impairment, and dependence risks. BNC210 is positioned to address these limitations by providing an anxiolytic effect without such side effects. With FDA Fast Track status and a Phase 3 program underway, Neuphoria aims to establish itself in the neuropsychiatric therapeutics market.

tl;dr

• Phase 3 AFFIRM-1 trial of BNC210 in Social Anxiety Disorder reached full enrollment (332 participants) on September 4, 2025; topline data expected early Q4 2025.
• On October 20, 2025, filed SEC prospectus to raise up to $15.48 million via at-the-market equity offering.
• Stock closed at $4.9970 on October 21, 2025, following recovery of Nasdaq compliance in July 2024. Future developments include AFFIRM-1 results and ongoing pipeline financing.